Genotype-informed docosahexaenoic acid dosing based on the FADS Indel to reduce preterm and prolonged gestation: A secondary analysis of the ADORE randomized trial

Source briefing · A concise briefing based on one linked source. It is intentionally shorter than a full FreedomWitness Evidence Engine analysis.

What the source reports

by Yan Ning Li, Kumar S. D. Kothapalli, Susan E. Carlson, Byron J. Gajewski, Emily A.

DeFranco, J. Thomas Brenna Background Spontaneous early preterm birth (EPB < 34 weeks) is a major contributor to newborn morbidity and mortality; it depends on ancestry, and preventive measures are limited. The insertion (I) allele of the fatty acid desaturase (FADS) Indel polymorphism (rs66698963) modulates FADS1 expression, and increases arachidonic acid synthesis, enhancing parturifacient prostaglandins. Omega-3 docosahexaenoic acid (DHA) inhibits this pathway. Whether FADS Indel genotype predicts response…

Evidence note: At this stage FreedomWitness is presenting what this source reports. This briefing does not independently prove every underlying claim and should be read together with the original material.

Source & verification

Primary source: PLOS Medicine · October 8, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.